Skip to main content
BioNxt Solutions Inc. logo

BioNxt Solutions Inc. — Investor Relations & Filings

Ticker · BNXT ISIN · CA0909741062 LEI · 254900VZ478Z39V2NM18 CSE Manufacturing
Open in API
Filings indexed 244 across all filing types
Latest filing 2024-12-24 Capital/Financing Update
Country CA Canada
Listing CSE BNXT

About BioNxt Solutions Inc.

https://bionxt.com/

BioNxt Solutions Inc. is a clinical-stage bioscience company focused on developing next-generation drug formulations and advanced delivery systems. The company specializes in high-performance solutions, including sublingual thin films and transdermal patches, designed to enhance bioavailability and patient compliance across critical therapeutic areas. BioNxt's R&D pipeline targets neurology, immunology, oncology, and mental health. Core platforms include advanced drug delivery systems for chronic diseases, a targeted chemotherapy platform designed to reduce systemic toxicity by delivering cytotoxic agents directly to tumors, and a proprietary library of engineered psychedelic compounds for neurological and psychiatric conditions. The company also develops diagnostic screening tests and active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a news release detailing the closing of a private placement of unsecured convertible debentures (amounts raised, interest rate, conversion terms, use of proceeds). It is an update on the company’s fundraising and capital structure changes, which matches the “Capital/Financing Update” category.
2024-12-24 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of the third tranche of a non-brokered convertible debenture private placement, detailing the principal amount raised, terms (interest rate, conversion price, maturity), use of proceeds, and related fees. It is a financing activity announcement rather than a financial report or regulatory filing. Therefore, it falls under Capital/Financing Update (CAP).
2024-12-23 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing R&D milestones and a product development roadmap for BNT23001. It is not a financial earnings release, regulatory form, meeting material, or dividend/notice. It’s a general market announcement of operational progress, fitting the fallback “Regulatory Filings” category for miscellaneous press releases. Thus, classify as RNS.
2024-12-09 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian securities regulatory form (Form 45-106F1 Report of Exempt Distribution) filed under National Instrument 45-106. It provides detailed party, issuer, distribution, purchaser, and compensation information required by the regulator for an exempt distribution. This is not an earnings release, financial report, proxy statement, or management presentation, nor is it simply an announcement of a report’s publication. It is a mandatory regulatory filing that does not fit into any more specific category, making “Regulatory Filings” (RNS) the appropriate classification.
2024-12-04 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing the development of a new sublingual thin-film for semaglutide. It does not present financial results, regulatory filings like an annual or interim report, management changes, voting results, capital transactions, or other structured filings. It is a general corporate announcement about product development. Since it does not fit any of the specific filing categories, it falls into the fallback category for miscellaneous announcements (Regulatory Filings).
2024-12-02 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing the closing of a private placement of unsecured convertible debentures, detailing amounts raised, interest rates, conversion terms, use of proceeds, and related financing fees. It is clearly an update on the company’s fundraising/capital activities, matching the definition for a Capital/Financing Update.
2024-11-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.